Nektar Therapeutics - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
NKTR Nasdaq 8731 http://www.nektar.com 22.24 Stock Up +0.07

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nektar Therapeutics

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug - Jul 21st, 2017 5:54 am
Nektar's NKTR-181 Positive in Human Abuse Potential Study - Jul 19th, 2017 3:14 pm
How This Biotech Could Dethrone Oxycodone In Treating Pain - Jul 18th, 2017 3:00 pm
Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise - Jul 18th, 2017 10:05 am
Nektar Shares Boosted by Promising Results on Opioid Addiction Study - Jul 18th, 2017 6:00 am
Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain - Jul 18th, 2017 6:00 am
Today's Research Reports on Trending Tickers: Nektar Therapeutics and Catalyst Pharmaceuticals Inc. - Jul 12th, 2017 6:10 am
Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London - Jul 10th, 2017 7:00 am
Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options - Jul 6th, 2017 7:00 am
Is This Small Biotech Headed For $1 Billion Market Cap — Or A Pitfall? - Jun 28th, 2017 2:10 pm
Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : June 22, 2017 - Jun 22nd, 2017 6:13 am
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why - Jun 16th, 2017 12:26 pm
ETFs with exposure to Nektar Therapeutics : June 9, 2017 - Jun 9th, 2017 11:48 am
Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City - Jun 6th, 2017 2:15 pm
Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - Jun 5th, 2017 7:00 am
Top Gainers in the Healthcare Sector: May 22–26, 2017 - May 31st, 2017 10:01 am
Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017? - May 30th, 2017 9:12 am
New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds - May 22nd, 2017 7:00 am
Bristol-Incyte Match Beats Dow's Merck In Combination Trials - May 19th, 2017 2:26 pm